New injection could tame teen hay fever
NCT ID NCT07678931
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether an injection called stapokibart can reduce nasal allergy symptoms like runny nose, congestion, sneezing, and itching in adolescents aged 12 to 17 with seasonal allergic rhinitis (hay fever). Participants receive either stapokibart or a placebo alongside their usual allergy medications. The goal is to see if the treatment improves symptom scores and quality of life over two to four weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stapokibart injection
- What this could lead to
- If effective, this could offer a new treatment option for teens with seasonal allergies that are not well controlled by standard therapies.
- What could go wrong
- This is a mid-stage trial with 136 participants, so results may not apply to everyone. The treatment may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS (SAR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beijing Tongren Hospital, CMU
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.